Market capitalization | $99.29m |
Enterprise Value | $-22.69m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.42 |
EV/Sales (TTM) EV/Sales | -2.13 |
P/S ratio (TTM) P/S ratio | 9.31 |
P/B ratio (TTM) P/B ratio | 16.85 |
Revenue (TTM) Revenue | $10.66m |
EBIT (operating result TTM) EBIT | $-62.50m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
6 Analysts have issued a Applied Therapeutics, Inc. forecast:
6 Analysts have issued a Applied Therapeutics, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 11 11 |
0%
0%
|
|
Gross Profit | 10 10 |
0%
0%
|
|
EBITDA | -62 -62 |
6%
6%
|
EBIT (Operating Income) EBIT | -63 -63 |
6%
6%
|
Net Profit | -97 -97 |
32%
32%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.
Head office | United States |
CEO | Les Funtleyder |
Employees | 25 |
Founded | 2016 |
Website | www.appliedtherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.